| Drug Name |
Gatifloxacin |
| Drug ID |
BADD_D01006 |
| Description |
Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan. |
| Indications and Usage |
For the treatment of bronchitis, sinusitis, community-acquired pneumonia, and skin infections (abscesses, wounds) caused by S. pneumoniae, H. influenzae, S. aureus, M. pneumoniae, C. pneumoniae, L. pneumophila, S. pyogenes |
| Marketing Status |
approved; investigational |
| ATC Code |
J01MA16; S01AE06 |
| DrugBank ID |
DB01044
|
| KEGG ID |
D00589; D08011
|
| MeSH ID |
D000077734
|
| PubChem ID |
5379
|
| TTD Drug ID |
D03CQE
|
| NDC Product Code |
53476-1155; 50383-189; 68180-435; 60758-615; 61314-672; 0023-3615 |
| UNII |
L4618BD7KJ
|
| Synonyms |
Gatifloxacin | 1-cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid | Gatifloxacine | Tequin | AM 1155 | AM-1155 | CG 5501 | BMS-206584 | BMS 206584 | BMS206584 | Zymar |
